Robert F. Kennedy Jr.’s Make America Healthy Again plan aims to reduce reliance on antidepressants by promoting informed consent, deprescribing when appropriate, and expanding non-drug treatments for mental health, especially among children and young people.
The debate over antidepressant use has been brewing for years, and this new push from HHS makes it official policy to favor review and restraint over reflexive prescribing. The department says it will encourage providers to weigh risks and benefits regularly and consider alternatives like psychotherapy, nutrition, family support, and exercise. This is being framed as moderation, not prohibition, but it changes the default approach clinicians have used for decades.
The federal health department will begin a series of steps intended to curb antidepressant use in the US, Robert F Kennedy Jr announced this week.
Antidepressants, specifically selective serotonin reuptake inhibitors, have long been a target for Kennedy, the Trump administration’s health secretary, who talked about the plans at an event on Monday hosted by the Make America Healthy Again Institute, an organization focused on advancing the Maha agenda. He has claimed without evidence that the drugs are linked to a rise in school shootings and has expressed concerns about weaning off the medications and withdrawal symptoms.
In a press release about the plans, the Department of Health and Human Services said its intent was to “curb psychiatric overprescribing” and promote “deprescribing when clinically indicated”.
This move will include guidance from CMS on how clinicians can be reimbursed for deprescribing and for delivering evidence-based nonpharmacological care. The plan points providers toward professional guidelines, tapering protocols, and FDA instructions for safely reducing doses when needed. For patients and families, that translates to more conversations about treatment goals and less chance of pills being the first option handed out in a short office visit.
In a Dear Colleague Letter [PDF] published today, HHS encourages providers to prioritize informed consent and shared decision-making, and to regularly review the risks and benefits of psychiatric medications with patients. The letter highlights nonmedication approaches, such as family support, psychotherapy, nutrition, and physical activity when clinically appropriate. Providers can also find information in the letter on billing codes that can be used to support the delivery of evidence-based nonmedication treatments.
In addition, the Centers for Medicare & Medicaid Services (CMS) released guidance for physicians and other practitioners on the importance of deprescribing and related medical care. This guidance clarifies how physicians and other practitioners can be paid for this type of care under Medicare, and also directs clinicians to widely recognized resources for deprescribing, including professional society guidelines, peer-reviewed deprescribing protocols, and the U.S. Food and Drug Administration (FDA) instructions for taper schedules.
Let’s be blunt: Republicans favor patient choice, informed consent, and pushing back against regulatory capture by Big Pharma. Encouraging nonpharmacological care aligns with conservative values of self-reliance, family involvement, and clinical judgment over one-size-fits-all prescriptions. If doctors are reimbursed for time spent counseling and supervising tapering, patients will get better care and pharma will no longer hold the first-mover advantage in mental health treatment.
Anecdote and frontline experience matter here. A practicing nurse-practitioner with years of emergency medicine experience told a close family member that “SSRI’s are way overprescribed. (A patient’s) withdrawal can be hell. Migraines, vision, and balance are off. All because someone threw a pill at them instead of suggesting exercise, sleep, and therapy.” That blunt appraisal gets to the heart of the policy drive: clinicians need to consider full-spectrum care before defaulting to medication.
Statistics back concern about broad antidepressant use: recent data suggest a sizable share of Americans take these drugs, and children are not immune to the trend. Even if many patients legitimately benefit from medication, the idea that medication should be the only accessible or encouraged path is what HHS seeks to change. Encouraging sensible alternatives does not deny medication exists; it restores balance to clinical decision-making.
There will be critics who frame any effort to curb prescribing as an overreach or as ill-informed meddling in clinical practice. That’s predictable, and the response is simple: the policy emphasizes shared decision-making and informed consent, not forced removal of treatments. Patients and families retain choice, while clinicians are nudged to review care plans and to use non-drug therapies where appropriate.
This policy also forces a practical conversation about incentives. Right now, certain treatments are more profitable than others, and that distorts care. Aligning payment codes to reward counseling, therapy coordination, and careful tapering helps fix that distortion and returns focus to outcomes rather than prescriptions filled. For conservatives who care about efficient, accountable healthcare, that is a sensible reform.
At its core, the MAHA plan on deprescribing signals a shift from medication as default to medication as one tool among many, with an emphasis on patient-centered choices and clinician accountability. Whether it accomplishes its goals will depend on implementation, clinician buy-in, and whether families can access the alternatives that the plan promotes.
Add comment